ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2008
Protection against Parkinson's disease progression: clinical experience.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 58 citations in OpenAlex.
- Article
- Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase.Molecular diversity · 2021Article
- Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase.Molecular diversity · 2019Article
- Inhibition of HDAC4 Attenuated JNK/c-Jun-Dependent Neuronal Apoptosis and Early Brain Injury Following Subarachnoid Hemorrhage by Transcriptionally Suppressing MKK7.Frontiers in cellular neuroscience · 2019Article
- Microglia and CNS Interleukin-1: Beyond Immunological Concepts.Frontiers in neurology · 2018Review
- Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Article
- Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.Translational neurodegeneration · 2013Article
- Defective autophagy in Parkinson's disease: role of oxidative stress.Molecular neurobiology · 2012Review
- Nicotine as a potential neuroprotective agent for Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2012Review
- Functional reduction of SK3-mediated currents precedes AMPA-receptor-mediated excitotoxicity in dopaminergic neurons.Neuropharmacology · 2011Article
- Missing pieces in the Parkinson's disease puzzle.Nature medicine · 2010Review
- Review
- Protein S-nitrosylation in health and disease: a current perspective.Trends in molecular medicine · 2009Review
- Antioxidant enzyme gene transfer for ischemic diseases.Advanced drug delivery reviews · 2009Review
- Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice.Neurobiology of disease · 2009Article
- Experimental therapeutics for dystonia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2008Review
- alpha-Synuclein: a therapeutic target for Parkinson's disease?Pharmacological researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatments with potential neuroprotective capability for Parkinson's disease (PD) have been investigated in randomized, controlled, clinical trials and other studies since the mid-1980s. Although promising leads have arisen, no therapy has been proven to halt or slow disease progression. Several large-scale studies have highlighted progress in methodology, as well as the frustrations of translating laboratory science to practical applications. This review summarizes findings from clinical trials with several classes of compounds, including monoamine oxidase-B inhibitors (selegiline, lazabemide, rasagiline), dopaminergic drugs (ropinirole, pramipexole, levodopa), antioxidant strategies (alpha-tocopherol), mitochondrial energy enhancers (coenzyme Q(10), creatine), antiapoptotic agents (TCH346, minocycline, CEP-1347), and antiglutamatergic compounds (riluzole). Beyond small-molecule pharmacology, gene therapy approaches, such as delivering neurotrophic substances (e.g., neurturin) by viral vector, are the next generation of treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.